HOME > News > Announcements > 2023.3.23 Glac Biotech’s Flagship Probiotic CP-9 Reaches New Heights With Breakthrough Patent in Neonatal Jaundice Resea
2023.3.23 Glac Biotech’s Flagship Probiotic CP-9 Reaches New Heights With Breakthrough Patent in Neonatal Jaundice Resea
Few probiotic strains earn the title of “star,” but for Glac Biotech, Bifidobacterium animalis subsp. lactis CP-9 has long held that reputation. Known for its exceptional stability, premium quality, and scalable production, CP-9 has consistently drawn high levels of interest at international exhibitions. In 2023, its reputation was elevated once again: CP-9 was shortlisted alongside the world’s top probiotic giants for the NutraIngredients Europe Awards, often called the “Oscars” of the food industry — a global acknowledgment of its gold-standard quality.
Tackling a Critical Challenge: Neonatal Jaundice
The recognition didn’t stop there. Glac’s R&D center has been steadily investing in new clinical directions, and recently CP-9 became the focus of groundbreaking work in neonatal jaundice.
Jaundice, caused by elevated bilirubin levels, affects 50–60% of newborns worldwide, with incidence rates surpassing 70% in Asia. Typically treated with phototherapy, the condition can lead to side effects: skin dryness from prolonged light exposure, or discomfort if eye protection is insufficient.
In Glac’s study, nearly 100 jaundiced newborns received CP-9 in combination with standard care. The results were striking — within just 24 hours, bilirubin levels dropped faster, and the duration of phototherapy was shortened. This not only demonstrated the strain’s safety and effectiveness, but also opened a door to improving the comfort and recovery of newborns at a vulnerable stage of life.
From Mother’s Milk to Global Patents
The story of CP-9 begins with breast milk, its natural source. Having undergone exhaustive safety evaluations and rigorous tests simulating stomach acid and bile salts, CP-9 has proven its resilience with exceptionally high survival rates.
Globally, the strain already boasts more than 30 patents, and now it adds another milestone: a newly granted patent for “Lactic Acid Bacteria Compositions for the Treatment or Prevention of Jaundice” (I 790820). This honor crowns years of work and reaffirms CP-9 as one of the most scientifically validated probiotic strains in the world.
A Future Defined by Science and Care
For Glac Biotech, CP-9 is more than just an ingredient — it is a symbol of what happens when cutting-edge research meets human need. From winning international awards to pioneering neonatal applications, CP-9 continues to redefine what probiotics can achieve.
As the company looks forward, its mission remains unchanged: to harness science not only for recognition, but for the well-being of people at every stage of life — from newborns to the elderly. With CP-9 leading the way, Glac Biotech is once again proving that probiotics can do more than support health — they can transform it.
References:
1.Outcomes of neonatal jaundice in Taiwan
2.Long-term neurodevelopmental outcomes of significant neonatal jaundice in Taiwan from 2000-2003: a nationwide, population-based cohort study
Tackling a Critical Challenge: Neonatal Jaundice
The recognition didn’t stop there. Glac’s R&D center has been steadily investing in new clinical directions, and recently CP-9 became the focus of groundbreaking work in neonatal jaundice.
Jaundice, caused by elevated bilirubin levels, affects 50–60% of newborns worldwide, with incidence rates surpassing 70% in Asia. Typically treated with phototherapy, the condition can lead to side effects: skin dryness from prolonged light exposure, or discomfort if eye protection is insufficient.
In Glac’s study, nearly 100 jaundiced newborns received CP-9 in combination with standard care. The results were striking — within just 24 hours, bilirubin levels dropped faster, and the duration of phototherapy was shortened. This not only demonstrated the strain’s safety and effectiveness, but also opened a door to improving the comfort and recovery of newborns at a vulnerable stage of life.
From Mother’s Milk to Global Patents
The story of CP-9 begins with breast milk, its natural source. Having undergone exhaustive safety evaluations and rigorous tests simulating stomach acid and bile salts, CP-9 has proven its resilience with exceptionally high survival rates.
Globally, the strain already boasts more than 30 patents, and now it adds another milestone: a newly granted patent for “Lactic Acid Bacteria Compositions for the Treatment or Prevention of Jaundice” (I 790820). This honor crowns years of work and reaffirms CP-9 as one of the most scientifically validated probiotic strains in the world.
A Future Defined by Science and Care
For Glac Biotech, CP-9 is more than just an ingredient — it is a symbol of what happens when cutting-edge research meets human need. From winning international awards to pioneering neonatal applications, CP-9 continues to redefine what probiotics can achieve.
As the company looks forward, its mission remains unchanged: to harness science not only for recognition, but for the well-being of people at every stage of life — from newborns to the elderly. With CP-9 leading the way, Glac Biotech is once again proving that probiotics can do more than support health — they can transform it.
References:
1.Outcomes of neonatal jaundice in Taiwan
2.Long-term neurodevelopmental outcomes of significant neonatal jaundice in Taiwan from 2000-2003: a nationwide, population-based cohort study
-
2024.3.29 Glac Biotech’s Totipro® PE0301 Wins NutraIngredients Award, Reinforcing Global Leadership in Postbiotics
-
Totipro® PE0401, the Postbiotic That Brings Health Within Reach — Making Daily Nutrition Simple and Joyful
-
2023.12.15 Glac Biotech’s PRONULIFE® LvUCare Wins Top Innovation Award from the Lactic Acid Bacteria Association